# OnCo record nct04229979 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04229979/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04229979", "NCT04229979" ;
  schema:name "Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2"@en ;
  schema:alternateName "REGAL"@en ;
  schema:description "A phase 3 trial of Azacitidine, Venetoclax, Decitabine and Cytarabine in acute myeloid leukaemia, run by Sellas Life Sciences Group, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04229979/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04229979> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-02-08" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/drugs/cytarabine/> ;
  onco:companies <https://onco.cc/companies/galena-biopharma/> .